Increasing burden of community-acquired pneumonia leading to hospitalisation, 1998–2014

T Phuong Quan,1,2 Nicola J Fawcett,1,2 John M Wrightson1,3 John Finney,1,2 David Wyllie,1,2 Katie Jeffery,3 Nicola Jones,3 Brian Shine,3 Lorraine Clarke,3 Derrick Crook,1,2,3 A Sarah Walker,1,2 Timothy E A Peto,1,2,3 on behalf of the Infections in Oxfordshire Research Database (IORD)

ABSTRACT

Background Community-acquired pneumonia (CAP) is a major cause of mortality and morbidity in many countries but few recent large-scale studies have examined trends in its incidence.

Methods Incidence of CAP leading to hospitalisation in one UK region (Oxfordshire) was calculated over calendar time using routinely collected diagnostic codes, and modelled using piecewise-linear Poisson regression. Further models considered other related diagnoses, typical administrative outcomes, and blood and microbiology test results at admission to determine whether CAP trends could be explained by changes in case-mix, coding practices or admission procedures.

Results CAP increased by 4.2%/year (95% CI 3.6 to 4.8) from 1998 to 2008, and subsequently much faster at 8.8%/year (95% CI 7.8 to 9.7) from 2009 to 2014. Pneumonia-related conditions also increased significantly over this period. Length of stay and 30-day mortality decreased slightly in later years, but the proportions with abnormal neutrophils, urea and C reactive protein (CRP) did not change (p>0.2). The proportion with severely abnormal CRP (>100 mg/L) decreased slightly in later years, but the proportions with abnormal CRP decreased in all age groups. Streptococcus pneumoniae was the most common causative organism found; however other organisms, particularly Enterobacteriaceae, increased in incidence over the study period (p<0.001).

Conclusions Hospitalisations for CAP have been increasing rapidly in Oxfordshire, particularly since 2008. There is little evidence that this is due only to changes in pneumonia coding, an ageing population or patients with substantially less severe disease being admitted more frequently. Healthcare planning to address potential further increases in admissions and consequent antibiotic prescribing should be a priority.

Beyond an actual increase in disease, the increases reported have many potential explanations, including changes in case-mix, improvements in diagnostic coding, changes in preferred codes (eg, ‘sepsis’ rather than ‘pneumonia’4) or changing admission practices, for example, admitting lower-severity cases. However, most research to date has used only administrative coding data sets, such as the UK Hospital Episodic Statistics or the US National (Nationwide) Inpatient Sample, which alone are unable to assess disease severity at presentation to hospital, and hence whether or not this affects admission practices. We therefore used the Infections in Oxfordshire Research Database (IORD)6 to investigate the hypothesis that changes in incidence of hospitalisations for CAP in Oxfordshire adults over the past 16 years could be explained by changes in case-mix, coding practices, disease severity at admission or bacterial aetiology.

METHODS

IORD contains all admissions to the Oxford University Hospitals NHS Foundation Trust from

Key messages

What is the key question?

► UK hospitalisations for pneumonia were found to be increasing more than expected between 1997 and 2009, but what is happening now, and is there anything we should be worrying about?

What is the bottom line?

► There is an alarming ongoing increase in pneumonia hospitalisations (at least in Oxfordshire), as well as changes in bacterial aetiology which have implications for antibiotic prescribing.

Why read on?

► We show that the increase is not just due to changes in population, documentation or admission practices by triangulating frequently used but arguably subjective data such as diagnostic codes against more reliably objective data such as laboratory tests.
April 1997 to date, linked with microbiology and biochemistry/ haematology laboratory results. The four Trust hospitals provide all acute care and all microbiology and pathology services in the region (~600 000 individuals). Out-of-hospital mortality is determined from a national information system into which UK-wide deaths are recorded.

This analysis considered UK financial years (April–March) ending 1998–2014 inclusive (avoiding splitting the winter peak across 2 years) and included only patients ≥18 years at admission. To restrict to community-acquired cases, we only included patients with a primary diagnostic code of pneumonia admitted to specialties where CAP would normally present, that is, acute general medicine (300), infectious diseases (350), emergency department (180), respiratory medicine (340) and geriatric medicine (430). If an admission contained multiple consultant episodes, only the first episode’s codes were used. Over the study period, these specialties accounted for 17 489/18 785 (93%) adult pneumonia admissions. All primary diagnostic codes in these specialties were grouped into diagnostically distinct categories by an acute medicine physician (referring to the Clinical Classifications software7), and reviewed by an infectious diseases specialist (see online supplementary material).

We also excluded all day cases (where a patient temporarily requires a bed but is not expected to stay overnight (173/17 489 (1%) adult pneumonia admissions)) as day cases had been recorded in different ways in different years. Trends in annual incidence were modelled using Poisson regression, with financial year as the only explanatory variable, and allowing a change in trend where this significantly improved model fit (see online supplementary methods; in brief, the deviance goodness-of-fit statistic from models allowing a change in trend where this significantly improved model fit (see online supplementary material). An infectious diseases specialist (see online supplementary material).

In sensitivity analyses, we modelled only the first pneumonia episode per person per year, as well as only the first pneumonia episode per person recorded since April 1997 (to determine if changes were driven by increases/decreases in readmissions rather than actual disease). We also separately considered cases of pneumonia where the patient had not been in hospital in the preceding 14 days, to exclude the possibility of them having acquired their pneumonia during a previous hospital admission.

Case-mix and population growth
Pneumonia disproportionately affects older people so to control for this we standardised admissions for age (and sex) for each year against the 1998 Oxfordshire population, and also adjusted for overall population size. Population estimates were obtained from the UK Office for National Statistics.9 9

Comorbidities also increase with age, and are often controlled for by calculating the Charlson comorbidity score10 for each episode. However, the completeness of secondary diagnostic codes has substantially improved over time11 (see online supplementary figure S1), and so the Charlson comorbidity score cannot be relied upon to measure comorbidities consistently over long time periods (see online supplementary figure S2).

Diagnostic coding
Under clinical uncertainty or multiple diagnoses, the choice of primary diagnostic code depends on many factors, including documentation quality, the clinical coder’s experience, the higher monetary tariff paid for certain codes, and quality improvement projects that may encourage the use of certain codes. Therefore, pneumonia cases may potentially be mislabelled as another lower respiratory disorder or vice versa, so we also modelled the incidence over time of likely alternative diagnoses, namely COPD, other lower respiratory tract infections, sepsis and non-specific viral infection (see online supplementary material). ‘Diagnostic-code-switching’ would be suggested if these incidence trends were opposite to that of pneumonia.

Disease severity and aetiology
To assess whether changes in disease severity of those being admitted to hospital could be contributing to changes in pneumonia incidence, we first considered those measures available in other administrative data sets, namely the outcomes length of stay, 30-day all-cause mortality and 30-day readmission. The major limitation of using such outcomes to assess CAP severity at presentation is that they are influenced by numerous factors during admission, for example, delayed discharge for social reasons or administrative changes in bed policy. As more robust measures of severity we therefore also modelled the median C reactive protein (CRP), urea and absolute neutrophil count (closest value within ±2 days of admission), as well as the proportion of these test results falling outside prescribed thresholds (CRP: >20 and >100 mg/L,13 urea: >7 mmol/L,14 neutrophils: <2 or >7 ×10⁹/L (hospital laboratory reference range)). Results from the Horton laboratory (which closed in October 2003 when all testing was transferred to a single site) were not available, and so only test results available for complete financial years were included, and a step-change added to the models at this time point to allow for case-mix differences between the hospitals. Test results were therefore available in 67–70% CAP admissions annually before 2004 and 90–97% thereafter.

Finally, we modelled the incidence and proportion of CAP admissions where microbiology cultures of blood or high-quality respiratory samples (ie, plural fluid or bronchoalveolar lavage) were taken (within ±2 days of admission), and any likely causative agents found (see online supplementary material). Where there were multiple microbiological tests within the window, the earliest positive pleural fluid sample was taken where available, otherwise the earliest positive blood sample, otherwise the earliest positive bronchoalveolar lavage sample. CAP sputum samples are not routinely analysed at the hospital laboratory owing to poor reliability and so were not included. Similarly to the haematology/biochemistry tests, microbiology results from the Horton laboratory were not available so only results available for complete financial years were included.

Trends in length of stay and median biomarkers were modelled using median (quantile) regression, and in other outcomes using Poisson regression. All analyses were conducted using Stata V13.1.

RESULTS
Between April 1997 and March 2014 there were 407 774 adult admissions into the relevant specialities, comprising 195 489 individuals. Of these admissions, 17 316 were for CAP. Just over half of CAP admissions (52%) were men and this proportion did not change significantly over time (p=0.53). Median age increased over time (p<0.001) from 74 years in 1997/1998 to 80 years in 2013/2014.

Raw CAP admissions rose from 598 in 1997/1998 to 1677 in 2013/2014, an overall rise of 180% (figure 1A). However, there
was strong evidence (p<0.001) this had not occurred uniformly, with admissions increasing by 4.2%/year (95% CI 3.6 to 4.8) through 2007/2008, but by 8.8%/year (95% CI 7.8 to 9.7) afterwards (table 1). Faster annual incidence increases post 2008 persisted after controlling for population changes (p<0.001 vs model with no trend-change), although the absolute increases were smaller. Annual incidence increases were also significantly faster post 2008 when including only the first pneumonia episode per person per year (p<0.001), and faster post 2007 when including only the first pneumonia episode per person ever recorded (p<0.001), eliminating the possibility that readmissions were driving overall increases. Patterns remained similar when excluding patients who had been in hospital in the preceding 14 days. Very few admissions (<30/year) were recorded as coming from nursing homes.

Admissions for other conditions which might be alternatively diagnosed as pneumonia also increased significantly during this time (figure 1A and table 1). However, in contrast to pneumonia, increases in COPD and in other lower respiratory infections were faster before 2005 and 2007, respectively, than subsequently, suggesting some diagnosis-code switching could be occurring. Comparing current incidence rates, CAP incidence rose significantly faster than COPD and other lower respiratory infections (p<0.001 and p=0.001, respectively), but there was no evidence of difference in trends compared with sepsis and non-specific viral infections (p=0.34 and p=0.98, respectively). CAP incidence also rose significantly faster compared with all the above conditions grouped together (p<0.001).

Admissions for other common infections also increased during the period (figure 1B), with lower urinary tract infections, skin and soft tissue infections, and upper respiratory infections all currently rising at significantly lower rates (p<0.001) than pneumonia, while gastroenteritis is currently rising significantly faster (p<0.001). However, lower urinary tract infections and gastroenteritis had very late trend-change points (2012 and 2011, respectively), and prior to this there was no evidence that either diagnosis was rising at a different rate to post-2008 pneumonia (p=0.45 and p=0.40, respectively).

Overall admissions (into the relevant specialties) increased, though with a current trend significantly slower than CAP (p<0.001). Similarly, admissions for all non-pneumonic infections and for all non-infections also increased over the study period (figure 1C), but with current trends significantly slower than CAP (p=0.02 and p<0.001, respectively).

Considering administrative outcomes of adult CAP admissions, 30-day all-cause mortality ranged from 22% to 29% over the study, increasing by 1.8%/year from 1998 to 2007 then decreasing by 3.1%/year (table 2). Median length of stay stayed constant at ~6 days from 1998 to 2005, then decreased by 0.25 days/year. Trends were similar in all age groups (figure 2). This suggests the threshold for admitting patients with CAP could have lowered in recent years, and/or care had improved. However, while 2–5% of patients were readmitted with pneumonia (as primary diagnosis) within 30 days of discharge, this significantly increased over the study, and similarly, all-cause readmissions increased from 2002 onwards. Competing-risks regression also confirmed that readmissions were increasing significantly faster than deaths post discharge (sub-HR=1.07/year (1.05 to 1.09)).

Considering biomarkers that should reflect disease severity at presentation more accurately than postadmission outcomes, median CRP increased slightly up to 2009 then decreased slightly thereafter (table 3); however, levels remained significantly elevated (median 94 mg/L in 2014). The proportion of results over 100 mg/L was stable up to 2009 at ~52% then decreased by 2.3%/year. Other biomarkers were mostly stable, with median urea increasing slightly up to 2004 then remaining at ~7.8 mmol/L, and median neutrophil counts stable up to 2011 then decreasing slightly thereafter (median 9.7×109/L in 2014). The proportion of these tests which were outside relevant thresholds did not change substantially over time (p=0.21, p=0.73, respectively). Again, trends were similar in all age groups (figure 2).

Between 53% and 69% of CAP admissions annually had blood or high-quality respiratory cultures performed, with this proportion decreasing over time (table 4), as did the proportion of...
with a positive culture result. However, because of the overall increase in CAP, the absolute numbers of CAP admissions with these cultures taken, and with positive culture results, increased over time. The most common organism overall was *Streptococcus pneumoniae* (48% of cases where a causative organism was found), followed by *Escherichia coli* (11%) and *Staphylococcus aureus* (7%). Incidence of CAP primarily associated with *Enterobacteriaceae* increased significantly over the study period (E. coli: 9.8%/year, p<0.001; *Klebsiella* spp: 12.3%/year, p=0.001; other *Enterobacteriaceae*: 10.6%/year, p=0.001) (figure 3), as did cases associated with anaerobes/ *Streptococcus* ‘milleri’ group bacteria (13.6%/year, p=0.01). Incidence of other traditional CAP-related organisms did not change significantly (*S. pneumoniae*: p=0.63; *S. aureus*: p=0.84; *Haemophilus influenzae*: p=0.50; *Pseudomonas aeruginosa*: p=0.25; other Gram-positives: p=0.25; other Gram-negatives: p=0.22). The increasing incidence of *Enterobacteriaceae*-associated CAP persisted even when excluding individuals who had been in hospital in the previous 14 days (see online supplementary figure S3); and the median (IQR) time from admission to specimen collection was −0.7 (−4.1 to 0.0) hours, suggesting this is highly unlikely to be driven by misclassified hospital-acquired pneumonia.

**DISCUSSION**

Hospital admissions for CAP are currently increasing by ~9% per year among Oxfordshire adults and cannot be attributed simply to a growing, ageing population. This is not an artefact...
of repeat admissions for the same illness episode nor an increase in hospital-acquired pneumonia as trends persisted when excluding all readmissions and when excluding those with any previous recent hospitalisations, respectively. Additionally, trends in admissions for reasons other than pneumonia differed significantly to CAP (table 1 and figure 1C), suggesting that the increases are not merely a reflection of overall changes in admission numbers.

The rise is also not explainable by 'diagnosis-code-switching' since hospitalisations for other, similar, diagnoses also increased during the same time period. However, the fact that pneumonia diagnoses increased at a faster rate after 2008 while COPD and other lower respiratory infections started to increase more slowly at around the same time suggests some limited diagnosis-switching could still be occurring.

An alternative explanation for the CAP increase is that more low-severity cases are presenting to hospital (where previously they were managed in primary care), and the decrease in length of stay and 30-day all-cause mortality over the latter part of the study period supports this hypothesis. However, the fact that readmissions for pneumonia increased over this time supports another plausible explanation for the shortening length of stay, namely an increased pressure for early discharge. The proportion of CAP admissions where blood or high-quality respiratory cultures were requested (a potential indicator of moderate-high severity), as well as CRP, also decreased in the latter part of the study; however, urea and neutrophils stayed fairly stable, and the actual magnitude of the CRP change was very small, with most individuals still having clearly abnormal values. Therefore there

Figure 2  Administrative outcomes and admission biomarkers for all community-acquired pneumonia admissions. (A) 30-day all-cause mortality rate (B) median length of stay (C) 30-day readmission rate (with pneumonia) post discharge (D) median C reactive protein (CRP) at admission (E) median urea at admission (F) median neutrophil count at admission. Vertical line represents step-change in availability of laboratory test results (see Methods).
does not seem to have been a clear shift towards admitting more low-severity cases, and despite the proportion of pneumonia cases warranting blood/respiratory cultures decreasing, the actual numbers of these cases (and therefore burden of CAP judged sufficiently severe to warrant requesting them) has continued to increase.

The main study strength lies in the use of linked electronic health records, which allow for triangulation of frequently used but arguably subjective data such as diagnostic codes, against more reliably objective data such as laboratory tests. Accuracy and completeness of diagnostic coding has changed over time as hospitals have adjusted to Payment by Results and to the publication of standardised mortality ratios, so relying on coding alone carries inherent risks. Although we have not attempted to measure the accuracy of the primary coding used in our hospitals, previous studies suggest it is sufficiently accurate for epidemiological analysis. We have, however, considered ‘diagnostic-code-switching’ in detail, as well as used only primary codes, which are subject to regular national audit.

Furthermore, linkage to national mortality data provides a more accurate outcome measure than the inhospital mortality used in most studies based on administrative data.

However, this strength is also the main limitation, since we are unable to investigate underlying mechanisms or specific

does not seem to have been a clear shift towards admitting more low-severity cases, and despite the proportion of pneumonia cases warranting blood/respiratory cultures decreasing, the actual numbers of these cases (and therefore burden of CAP judged sufficiently severe to warrant requesting them) has continued to increase.

The main study strength lies in the use of linked electronic health records, which allow for triangulation of frequently used but arguably subjective data such as diagnostic codes, against more reliably objective data such as laboratory tests. Accuracy and completeness of diagnostic coding has changed over time as hospitals have adjusted to Payment by Results and to the publication of standardised mortality ratios, so relying on coding alone carries inherent risks. Although we have not attempted to measure the accuracy of the primary coding used in our hospitals, previous studies suggest it is sufficiently accurate for epidemiological analysis. We have, however, considered ‘diagnostic-code-switching’ in detail, as well as used only primary codes, which are subject to regular national audit.

Furthermore, linkage to national mortality data provides a more accurate outcome measure than the inhospital mortality used in most studies based on administrative data.

However, this strength is also the main limitation, since we are unable to investigate underlying mechanisms or specific

Table 3 Annual trends in admission biomarkers (in those admitted for pneumonia)

<table>
<thead>
<tr>
<th></th>
<th>Initial change* per year (95% CI)</th>
<th>Year of rate-change†</th>
<th>Subsequent change* per year (95% CI)</th>
<th>Direction of change‡</th>
<th>Estimate in 2014§</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median CRP (mg/L)</td>
<td>2.68 (0.18 to 5.17)</td>
<td>2009</td>
<td>−4.60 (−6.48 to −2.72)</td>
<td>↓</td>
<td>94</td>
</tr>
<tr>
<td>Median urea (mmol/L)</td>
<td>0.12 (0.02 to 0.21)</td>
<td>2004</td>
<td>−0.01 (−0.05 to 0.03)</td>
<td>↑ ↔</td>
<td>7.8</td>
</tr>
<tr>
<td>Median neutrophils (&gt;10^9/L)</td>
<td>0.04 (−0.02 to 0.10)</td>
<td>2011</td>
<td>−0.16 (−0.28 to −0.04)</td>
<td>↓ ↔</td>
<td>9.7</td>
</tr>
<tr>
<td>Proportion CRP &gt;20 mg/L</td>
<td>−0.1 (−0.8 to 0.6)</td>
<td>−</td>
<td>−</td>
<td></td>
<td>0.84</td>
</tr>
<tr>
<td>Proportion CRP &gt;100 mg/L</td>
<td>1.0 (−1.1 to 3.1)</td>
<td>2009</td>
<td>−2.3 (−3.8 to −0.7)</td>
<td>↓</td>
<td>0.48</td>
</tr>
<tr>
<td>Proportion urea &gt;7 mmol/L</td>
<td>0.5 (−0.3 to 1.3)</td>
<td>−</td>
<td>−</td>
<td></td>
<td>0.58</td>
</tr>
<tr>
<td>Proportion neutrophils &lt;2 or &gt;7×10^9/L</td>
<td>−0.1 (−0.8 to 0.6)</td>
<td>−</td>
<td>−</td>
<td></td>
<td>0.75</td>
</tr>
</tbody>
</table>

Median values modelled using piecewise median regression, all other trends using piecewise linear Poisson regression.

*Absolute change in median values, percentage change in rate trend for proportions outside thresholds (out of those which had a test).
†Allowing change in trend over time if significant improvement over linear trend alone (p<0.05), with year of the change point chosen by profile likelihood§ (see Methods).
‡Single arrows represent direction of change over the whole time period; paired arrows represent direction and relative size of change in the periods before and after the year when data suggested trend in rates changed (as in †).
§Proportion of admissions/median value, as estimated by the best-fitting model as presented in the table.

CRP, C reactive protein.

Table 4 Annual trends in microbiology results (in those admitted for pneumonia)

<table>
<thead>
<tr>
<th></th>
<th>Initial % change per year (95% CI)</th>
<th>Year of rate-change*</th>
<th>Subsequent % change per year (95% CI)</th>
<th>Direction of change‡</th>
<th>Estimate in 2014§</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proportion of pneumonias with Blood or high-quality respiratory culture taken</td>
<td>−3.9 (−5.5 to −2.2)</td>
<td>2004</td>
<td>−1.1 (−1.9 to −0.3)</td>
<td>↓</td>
<td>0.62</td>
</tr>
<tr>
<td>Any potentially causative bacterial organism found</td>
<td>−3.4 (−5.6 to −1.1)</td>
<td>−</td>
<td>↓</td>
<td>0.05</td>
<td></td>
</tr>
<tr>
<td>Incidence of pneumonia with Blood or high-quality respiratory culture taken</td>
<td>2.1 (0.5 to 3.8)</td>
<td>2007</td>
<td>7.2 (6.3 to 8.2)</td>
<td>↑</td>
<td>1024</td>
</tr>
<tr>
<td>Any potentially causative bacterial organism found</td>
<td>3.8 (1.3 to 6.3)</td>
<td>−</td>
<td>↑</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>S. pneumoniae</td>
<td>−1.0 (−4.4 to 2.5)</td>
<td>−</td>
<td>−</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>S. aureus</td>
<td>0.2 (−8.4 to 9.6)</td>
<td>−</td>
<td>←</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>E. coli</td>
<td>9.8 (5.4 to 14.5)</td>
<td>−</td>
<td>↑</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Klebsiella spp</td>
<td>12.3 (4.8 to 20.2)</td>
<td>−</td>
<td>↑</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>P. aeruginosa</td>
<td>8.6 (−5.6 to 25.0)</td>
<td>−</td>
<td>←</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>H. influenzae</td>
<td>4.5 (−7.7 to 18.3)</td>
<td>−</td>
<td>←</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Other Enterobacteriaceae</td>
<td>10.6 (4.4 to 17.3)</td>
<td>−</td>
<td>↑</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Anaerobes/S. Milleri</td>
<td>13.6 (2.8 to 25.6)</td>
<td>−</td>
<td>↑</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Other Gram-positives</td>
<td>2.3 (−1.5 to 6.3)</td>
<td>−</td>
<td>←</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Other Gram-negatives</td>
<td>35.0 (−16.6 to 118.6)</td>
<td>−</td>
<td>←</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Mixed organisms</td>
<td>7.8 (0.8 to 15.4)</td>
<td>−</td>
<td>↑</td>
<td>4</td>
<td></td>
</tr>
</tbody>
</table>

All trends modelled using piecewise linear Poisson regression.

*Allowing change in trend over time if significant improvement over linear trend alone (p<0.05), with year of the change point chosen by profile likelihood§ (see Methods).
†Single arrows represent direction of change over the whole time period; paired arrows represent direction and relative size of change in the periods before and after the year when data suggested trend in rates changed (as in †).
‡Proportion/number of admissions, as estimated by the best-fitting model as presented in the table.
Microbiologically confirmed community-acquired pneumonia spells by causative organism (taken within 2 days of admission).

Figure 3

- Other organisms
- Mixed organisms
- S. aureus
- P. aeruginosa
- S. pneumoniae and other Gram positives
- All Enterobacteriaceae
- Pneumonia

Causes for the observed increases in CAP, and second, regardless of cause, what should we do about it? We have investigated several potential causes, but further possibilities include changes in levels of deprivation, an increase in comorbidities not captured within our data (given the confounding of the Charlson comorbidity score by coding depth [see online supplementary figures S1 and S2]) and reduced access to out-of-hours primary care leading people to come directly to hospital. Nevertheless, it is likely that multiple factors are contributing to the increase, rather than there being a single cause. Historically, pneumonia has been considered predominantly bacterial in aetiology, with *S. pneumoniae* the leading organism. However, we found a causative organism relatively rarely, in only 5% of cases in 2014 (8% where a culture was performed), potentially because of emphasis on early antibiotic initiation in emergency admissions, though also likely due to inherent difficulties in isolating organisms using culture-based methods. Vaccination programmes have significantly reduced the incidence of invasive pneumococcal disease in southern England (although not everywhere), but *S. pneumoniae* was still the most common causative organism found. However, its dominance is decreasing, and other organisms, particularly *Enterobacteriaceae* such as *E. coli* and *Klebsiella* spp. are becoming more prevalent. This is particularly concerning given their high rates of resistance to empirical antibiotics commonly recommended for CAP.

Although these pathogens have traditionally been viewed as associated with hospital-acquired pneumonia, we found similar CAP trends in patients without any recent previous hospital exposure, and specimens were taken very close to admission, suggesting this is highly unlikely to be driven by misclassified hospital-acquired pneumonia. There were no changes in hospital procedures regarding specimen collection processing that could have caused this: in any case such changes would be associated with an immediate incidence change rather than the gradual year-on-year increase we observed.

Respiratory tract infections are the most common indication for hospital antibiotic prescribing in the UK, accounting for over 30% of prescriptions. Thus CAP increases will drive increases in antibiotic prescribing and, unaddressed, hinder our best attempts to reduce antibiotic use, a key priority given increasing antimicrobial resistance. Animal studies suggest that antibiotic-driven microbiota depletion can impair subsequent responses to influenza and bacterial challenges, raising the intriguing possibility that increasing use of antibiotics to treat presumed bacterial infections could actually be having the unintended consequence of increasing their incidence. Further respiratory microbiome studies could investigate this hypothesis in humans. We are unable to assess whether non-microbiologically confirmed CAP was actually viral with the data available, and while H1N1 pandemic influenza may have been partially responsible for increases in 2009/2010, this would not explain the ever-increasing trend. Developing rapid point-of-care diagnostics to identify viral versus bacterial aetiology will be crucial to support the clinician in balancing the timely administration of antibiotics (emphasised by national and international guidelines), against reducing unnecessary antibiotic prescriptions. A better understanding of short-course or tailored antibiotic durations may also assist in reducing antibiotic exposure.

In summary, this study suggests that rather than discounting increases in pneumonia admissions as simply indicative of a growing, ageing population, or an artefact of documentation or healthcare-seeking behaviour, we should be actively searching for the reasons behind the increase, as well as planning our healthcare systems appropriately—for the increase in admissions—and to mitigate the potential ‘collateral damage’ of
antimicrobial resistance that may otherwise be seen as more and more patients are treated for pneumonia.

Acknowledgements The authors thank all the people of Oxfordshire who contribute to the Infections in Oxfordshire Research Database. Research Database Team: R Alistair, C Burch, DCW Crook, J Davies, J Finney, J Gearing (community), L O’Connor, TEA Petö (Pi), TP Quan, J Robinson (community), B Shire, AS Walker, D Waller, D Wylie. Patient and Public Panel: G Blower, C Mancey, P McLoughlin, B Nicholls.

Contributors TPO cleaned and analysed the data, and drafted and revised the paper. NIF and JMWW provided clinical guidance, categorised the data, and contributed to the discussion. BS and LC provided access to underlying laboratory data, JF and DW constructed and manage the routine electronic database. ASW and TEAP supervised and directed the analysis. All authors reviewed the paper for important intellectual content and approved the final draft. TPO, ASW and TEAP are guarantors for the study.

Funding This work was supported by the National Institute for Health Research Oxford Biomedical Research Centre and the Oxford NIHR Health Protection Unit (SRU 12-0104/); a NIHR Research Methods Fellowship to TPO (MET 11-27); and a Medical Research Council UK Clinical Research Training Fellowship to NIF (MR/M003736/1).

Disclaimer The study sponsor (OUH) had no role in the study design; in the collection, analysis or interpretation of data; in the writing of the report; or in the decision to submit the article for publication. The study was conducted independently of the funder (the National Institute for Health Research). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.

Competing interests None declared.

Ethics approval IORD has Research Ethics Committee and Health Research Authority approval as a generic electronic research database.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement The aggregate data by financial year analysed in this study is available from the corresponding author. Requests for anonymised licenses/by/4.0/ provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.

REFERENCES

SUPPLEMENTARY MATERIAL

(A) Further inclusion criteria and categorisation of ICD-10 diagnostic codes

Pneumonia:
A310 Pulmonary mycobacterial infection
A420 Pulmonary actinomycosis
A481 Legionnaires' disease
B012 Varicella pneumonia
B052 Measles complicated by pneumonia
B250 Cytomegaloviral pneumonitis
B59 Pneumocystosis
J100 Influenza with pneumonia, other influenza virus identified
J110 Influenza with pneumonia, virus not identified
J128 Other viral pneumonia
J129 Viral pneumonia, unspecified
J13 Pneumonia due to Streptococcus pneumoniae
J14 Pneumonia due to Haemophilus influenzae
J150 Pneumonia due to Klebsiella pneumoniae
J151 Pneumonia due to Pseudomonas
J152 Pneumonia due to staphylococcus
J153 Pneumonia due to streptococcus, group B
J154 Pneumonia due to other streptococci
J155 Pneumonia due to Escherichia coli
J156 Pneumonia due to other aerobic Gram-negative bacteria
J157 Pneumonia due to Mycoplasma pneumoniae
J158 Other bacterial pneumonia
J159 Bacterial pneumonia, unspecified
J168 Pneumonia due to other specified infectious organisms
J172 Pneumonia in mycoses
J180 Bronchopneumonia, unspecified
J181 Lobar pneumonia, unspecified
J182 Hypostatic pneumonia, unspecified
J188 Other pneumonia, organism unspecified
J189 Pneumonia, unspecified
J690 Pneumonitis due to food and vomit
J850 Gangrene and necrosis of lung
J851 Abscess of lung with pneumonia

Chronic obstructive pulmonary disease:
J40 Bronchitis, not specified as acute or chronic
J410 Simple chronic bronchitis
J42 Unspecified chronic bronchitis
J431 Panlobular emphysema
J432 Centrilobular emphysema
J438 Other emphysema
J439 Emphysema, unspecified
J441 Chronic obstructive pulmonary disease with acute exacerbation, unspecified
J448 Other specified chronic obstructive pulmonary disease
J449 Chronic obstructive pulmonary disease, unspecified

Other lower respiratory tract infections
J200 Acute bronchitis due to Mycoplasma pneumoniae
J208 Acute bronchitis due to other specified organisms
J209 Acute bronchitis, unspecified
J219 Acute bronchiolitis, unspecified
J22 Unspecified acute lower respiratory infection
J852 Abscess of lung without pneumonia

Nonspecific viral infections:
Viral infection, unspecified

Sepsis:
A021 Salmonella sepsis
A392 Acute meningococcaemia
A394 Meningococcaemia, unspecified
A400 Sepsis due to streptococcus, group A
A401 Sepsis due to streptococcus, group B
A402 Sepsis due to streptococcus, group D
A403 Sepsis due to Streptococcus pneumoniae
A408 Other streptococcal sepsis
A409 Streptococcal sepsis, unspecified
A410 Sepsis due to Staphylococcus aureus
A411 Sepsis due to other specified staphylococcus
A412 Sepsis due to unspecified staphylococcus
A414 Sepsis due to anaerobes
A415 Sepsis due to other Gram-negative organisms
A418 Other specified sepsis
A419 Sepsis, unspecified
R572 Septic shock

Skin/soft tissue infections:
L030 Cellulitis of finger and toe
L031 Cellulitis of other parts of limb
L032 Cellulitis of face
L033 Cellulitis of trunk
L038 Cellulitis of other sites
L039 Cellulitis, unspecified
L088 Other specified local infections of skin and subcutaneous tissue
L089 Local infection of skin and subcutaneous tissue, unspecified
M7112 Other infective bursitis, Upper arm
M725 Necrotizing fasciitis
M7250 Necrotizing fasciitis, Multiple sites
M7251 Necrotizing fasciitis, Shoulder region
M7252 Necrotizing fasciitis, Upper arm
M7253 Necrotizing fasciitis, Forearm
M7255 Necrotizing fasciitis, Pelvic region and thigh
M7256 Necrotizing fasciitis, Lower leg
M7257 Necrotizing fasciitis, Ankle and foot
M7258 Necrotizing fasciitis, Other
M7259 Necrotizing fasciitis, Site unspecified
M726 Necrotizing fasciitis
M7263 Necrotizing fasciitis, Forearm
M7266 Necrotizing fasciitis, Lower leg

Upper respiratory infections:
A370 Whooping cough due to Bordetella pertussis
A379 Whooping cough, unspecified
J00 Acute nasopharyngitis [common cold]
J010 Acute maxillary sinusitis
J011 Acute frontal sinusitis
J013 Acute sphenoidal sinusitis
J018 Other acute sinusitis
J019 Acute sinusitis, unspecified
J020 Streptococcal pharyngitis
J028 Acute pharyngitis due to other specified organisms
J029 Acute pharyngitis, unspecified
J030 Streptococcal tonsillitis
J038 Acute tonsillitis due to other specified organisms
J039 Acute tonsillitis, unspecified
J040 Acute laryngitis
J041 Acute tracheitis
J042 Acute laryngotracheitis
J050 Acute obstructive laryngitis [croup]
J051 Acute epiglottitis
J068 Other acute upper respiratory infections of multiple sites
J069 Acute upper respiratory infection, unspecified
J320 Chronic maxillary sinusitis
J321 Chronic frontal sinusitis
J322 Chronic ethmoidal sinusitis
J323 Chronic sphenoidal sinusitis
J328 Other chronic sinusitis
J329 Chronic sinusitis, unspecified
J36 Peritonsillar abscess
J390 Retropharyngeal and parapharyngeal abscess
J391 Other abscess of pharynx

Lower urinary tract infections:
N300 Acute cystitis
N308 Other cystitis
N309 Cystitis, unspecified
N340 Urethral abscess
N342 Other urethritis
N390 Urinary tract infection, site not specified
O233 Infections of other parts of urinary tract in pregnancy
O234 Unspecified infection of urinary tract in pregnancy
O239 Other and unspecified genitourinary tract infection in pregnancy
O862 Urinary tract infection following delivery

Gastroenteritis:
A010 Typhoid fever
A011 Paratyphoid fever A
A014 Paratyphoid fever, unspecified
A020 Salmonella enteritis
A028 Other specified salmonellosis infections
A029 Salmonella infection, unspecified
A044 Other intestinal Escherichia coli infections
A045 Campylobacter enteritis
A046 Enteritis due to Yersinia enterocolitica
A048 Other specified bacterial intestinal infections
A049 Bacterial intestinal infection, unspecified
A059 Bacterial foodborne intoxication, unspecified
A081 Acute gastroenteropathy due to Norwalk agent
A083 Other viral enteritis
A084 Viral intestinal infection, unspecified
A085 Other specified intestinal infections
A09 Other gastroenteritis and colitis of infectious and unspecified origin
A099 Gastroenteritis and colitis of unspecified origin

All infections (excluding pneumonia):
Available on request

All non-infections:
Available on request
(B) – Microbiology samples included and organisms cultured from them defined as plausibly causative for pneumonia or excluded

Specimens included[26]: blood for culture, pleural fluid, and bronchoalveolar lavage

Organisms cultured from these specimens included as plausibly causative for pneumonia, or excluded completely (i.e. test result counted as negative).

<table>
<thead>
<tr>
<th>Specifically included as plausibly causing pneumonia (n)</th>
<th>Specifically excluded (i.e. test counted as negative)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Streptococcus pneumoniae (480)</td>
<td>Actinobacter baumannii</td>
</tr>
<tr>
<td>Escherichia coli (117)</td>
<td>Acinetobacter lwoffii</td>
</tr>
<tr>
<td>Staphylococcus aureus (52)</td>
<td>Acinetobacter radioreistant</td>
</tr>
<tr>
<td>Methicillin resistant staphylococcus aureus (25)</td>
<td>Actinomycetes bovis</td>
</tr>
<tr>
<td>Haemophilus influenzae (40)</td>
<td>Aerobic spore bearer</td>
</tr>
<tr>
<td>Pseudomonas aeruginosa (35)</td>
<td>Aerococcus species</td>
</tr>
<tr>
<td>Klebsiella species:</td>
<td>Aerococcus viridans</td>
</tr>
<tr>
<td>Klebsiella pneumoniae (40)</td>
<td>Bacillus species</td>
</tr>
<tr>
<td>Klebsiella oxytocca (6)</td>
<td>Candida</td>
</tr>
<tr>
<td>Klebsiella species (1)</td>
<td>Candida albicans</td>
</tr>
<tr>
<td>Other Enterobacteriaceae:</td>
<td>Candida glabrata</td>
</tr>
<tr>
<td>Citrobacter braakii (1)</td>
<td>Candida species</td>
</tr>
<tr>
<td>Citrobacter freundii (1)</td>
<td>Coagulase negative staphylococcus</td>
</tr>
<tr>
<td>Citrobacter species (2)</td>
<td>Colonies</td>
</tr>
<tr>
<td>Coliforms (23)</td>
<td>Corynebacterium afermentans</td>
</tr>
<tr>
<td>Enteroctobacter aerogenes (2)</td>
<td>Corynebacterium amycolatum</td>
</tr>
<tr>
<td>Enterobacter cloacae (9)</td>
<td>Corynebacterium jeikeium</td>
</tr>
<tr>
<td>Morganella morgani (1)</td>
<td>Corynebacterium striatum</td>
</tr>
<tr>
<td>Nonfermenting coliform (1)</td>
<td>Diphtheroids</td>
</tr>
<tr>
<td>Proteus mirabilis (19)</td>
<td>Enterococci</td>
</tr>
<tr>
<td>Proteus species (2)</td>
<td>Enterococcus faecalis group D</td>
</tr>
<tr>
<td>Proteus vulgaris (5)</td>
<td>Enterococcus faecium group D</td>
</tr>
<tr>
<td>Providencia species (1)</td>
<td>Enterorococcus species</td>
</tr>
<tr>
<td>Salmonella species (1)</td>
<td>Gemella haemolyans</td>
</tr>
<tr>
<td>Serratia marcescens (2)</td>
<td>Gemella morbillorum</td>
</tr>
<tr>
<td>Yersinia enteroxocolitica (1)</td>
<td>Lactobacillus casei</td>
</tr>
<tr>
<td>Anaerobes/Streptococcus milleri:</td>
<td>Lactobacillus species</td>
</tr>
<tr>
<td>Bacteroides fragilis (2)</td>
<td>Listeria monocytogenes</td>
</tr>
<tr>
<td>Bacteroides intermedius (1)</td>
<td>Micrococcus</td>
</tr>
<tr>
<td>Bacteroides uniformis (1)</td>
<td>Micrococcus luteus</td>
</tr>
<tr>
<td>Clostridium species (5)</td>
<td>Micrococcus species</td>
</tr>
<tr>
<td>Mixed anaerobes isolated sensitive to metronidazole. (5)</td>
<td>Moraxella catarrhalis (brunhamella catarrhalis)</td>
</tr>
<tr>
<td>Streptococcus anginosus (milleri group) (2)</td>
<td>Moraxella species</td>
</tr>
<tr>
<td>Streptococcus constellatus (milleri group) (2)</td>
<td>Neisseria species</td>
</tr>
<tr>
<td>Streptococcus intermedius (milleri group) (1)</td>
<td>Non lactose fermenting Gram negative rods</td>
</tr>
<tr>
<td>Streptococcus milleri (7)</td>
<td>Pasteurella multocida</td>
</tr>
<tr>
<td>Other Gram-positives:</td>
<td>Propionibacterium acnes</td>
</tr>
<tr>
<td>Alpha haemolytic streptococci (64)</td>
<td>Propionibacterium species</td>
</tr>
<tr>
<td>Beta haemolytic streptococci (1)</td>
<td>Pseudomonas luteola</td>
</tr>
<tr>
<td>Group A streptococci (24)</td>
<td>Pseudomonas species</td>
</tr>
<tr>
<td>Streptococci (8)</td>
<td>Pseudomonas stutzeri</td>
</tr>
<tr>
<td>Streptococci, beta haemolytic group B (5)</td>
<td>Rhodococcus species</td>
</tr>
<tr>
<td>Streptococci, beta haemolytic group C (5)</td>
<td>Rothia dentocariosa</td>
</tr>
<tr>
<td>Streptococci, beta haemolytic group G (12)</td>
<td>Staphylococcus capitis</td>
</tr>
<tr>
<td>Streptococcus bovis (1)</td>
<td>Staphylococcus epidermidis(CONS)</td>
</tr>
<tr>
<td>Streptococcus dysgalactiae (serogroup C/G) (1)</td>
<td>Staphylococcus haemolytic</td>
</tr>
<tr>
<td>Streptococcus equisimilis (1)</td>
<td>Stenotrophomonas maltophilia</td>
</tr>
<tr>
<td>Streptococcus gallolyticus (strept.bovis biotype I) (1)</td>
<td></td>
</tr>
<tr>
<td>Streptococcus mitis (8)</td>
<td></td>
</tr>
<tr>
<td>Other Gram-negatives:</td>
<td></td>
</tr>
<tr>
<td>Capnocytophaga canimorsus (1)</td>
<td></td>
</tr>
<tr>
<td>Eikenella corrodens (1)</td>
<td></td>
</tr>
<tr>
<td>Haemophilus species (3)</td>
<td></td>
</tr>
<tr>
<td>Neisseria meningitidis (1)</td>
<td></td>
</tr>
<tr>
<td>Acinetobacter baumannii</td>
<td></td>
</tr>
<tr>
<td>Acinetobacter lwoffii</td>
<td></td>
</tr>
<tr>
<td>Acinetobacter radioreistant</td>
<td></td>
</tr>
<tr>
<td>Actinomycetes bovis</td>
<td></td>
</tr>
<tr>
<td>Aerobic spore bearer</td>
<td></td>
</tr>
<tr>
<td>Aerococcus species</td>
<td></td>
</tr>
<tr>
<td>Aerococcus viridans</td>
<td></td>
</tr>
<tr>
<td>Bacillus species</td>
<td></td>
</tr>
<tr>
<td>Candida</td>
<td></td>
</tr>
<tr>
<td>Candida albicans</td>
<td></td>
</tr>
<tr>
<td>Candida glabrata</td>
<td></td>
</tr>
<tr>
<td>Candida species</td>
<td></td>
</tr>
<tr>
<td>Coagulase negative staphylococcus</td>
<td></td>
</tr>
<tr>
<td>Colonies</td>
<td></td>
</tr>
<tr>
<td>Corynebacterium afermentans</td>
<td></td>
</tr>
<tr>
<td>Corynebacterium amycolatum</td>
<td></td>
</tr>
<tr>
<td>Corynebacterium jeikeium</td>
<td></td>
</tr>
<tr>
<td>Corynebacterium striatum</td>
<td></td>
</tr>
<tr>
<td>Diphtheroids</td>
<td></td>
</tr>
<tr>
<td>Enterococci</td>
<td></td>
</tr>
<tr>
<td>Enterococcus faecalis group D</td>
<td></td>
</tr>
<tr>
<td>Enterococcus faecium group D</td>
<td></td>
</tr>
<tr>
<td>Enterorococcus species</td>
<td></td>
</tr>
<tr>
<td>Gemella haemolyans</td>
<td></td>
</tr>
<tr>
<td>Gemella morbillorum</td>
<td></td>
</tr>
<tr>
<td>Lactobacillus casei</td>
<td></td>
</tr>
<tr>
<td>Lactobacillus species</td>
<td></td>
</tr>
<tr>
<td>Listeria monocytogenes</td>
<td></td>
</tr>
<tr>
<td>Micrococcus</td>
<td></td>
</tr>
<tr>
<td>Micrococcus luteus</td>
<td></td>
</tr>
<tr>
<td>Micrococcus species</td>
<td></td>
</tr>
<tr>
<td>Moraxella catarrhalis (brunhamella catarrhalis)</td>
<td></td>
</tr>
<tr>
<td>Moraxella species</td>
<td></td>
</tr>
<tr>
<td>Neisseria species</td>
<td></td>
</tr>
<tr>
<td>Non lactose fermenting Gram negative rods</td>
<td></td>
</tr>
<tr>
<td>Pasteurella multocida</td>
<td></td>
</tr>
<tr>
<td>Propionibacterium acnes</td>
<td></td>
</tr>
<tr>
<td>Propionibacterium species</td>
<td></td>
</tr>
<tr>
<td>Pseudomonas luteola</td>
<td></td>
</tr>
<tr>
<td>Pseudomonas species</td>
<td></td>
</tr>
<tr>
<td>Pseudomonas stutzeri</td>
<td></td>
</tr>
<tr>
<td>Rhodococcus species</td>
<td></td>
</tr>
<tr>
<td>Rothia dentocariosa</td>
<td></td>
</tr>
<tr>
<td>Staphylococcus capitis</td>
<td></td>
</tr>
<tr>
<td>Staphylococcus epidermidis(CONS)</td>
<td></td>
</tr>
<tr>
<td>Staphylococcus haemolytic</td>
<td></td>
</tr>
<tr>
<td>Stenotrophomonas maltophilia</td>
<td></td>
</tr>
</tbody>
</table>
Supplementary Methods

For piecewise linear Poisson regression, data was aggregated by UK financial year (Apr-Mar) and separate models were built for each potential change-point between 2000 and 2012 inclusive, using two linear piecewise linear functions (with the standard Poisson log link). The model which produced the lowest deviance goodness-of-fit statistic was chosen as the best two-piece model (a standard profile likelihood[8] approach). This model was then compared to the model with a single linear trend using a chi-squared test of difference in deviance, and the two-piece model chosen if it was a significantly (p<0.05) better fit.

Piecewise linear median regression was conducted similarly, with change-point model selection using the pseudo-R-squared statistic, and the best two-piece model chosen over the single trend model if an F-test of before-and-after trends showed a significant (p<0.05) difference.
Supplementary Figure 1. Coding depth – number of diagnostic codes recorded per CAP admission
Note: electronic recording of secondary diagnosis codes was introduced in January 2006.

Supplementary Figure 2. Charlson severity score per CAP admission

Supplementary Figure 3. Prior recent hospitalisation of patients with Enterobacteriaceae cultured